Key facts
- It has raised $376.8M; the latest was Later Stage VC ($295.0M) in Jul 2025.
- Status: Privately Held (backing).
- ·Watchlist + deal alerts for Paragon Biosciences
- ·The full record, as it builds
Funding rounds
No funding rounds for Paragon Biosciences are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Paragon Biosciences
Developer of biology-driven ventures designed to address complex medical conditions. The company's platform integrates scientific research, operational support, and capital investment, enabling the life sciences market to translate early-stage biological discoveries into scalable therapeutic products, improve commercialization pathways, and reduce the time and risk typically associated with biotech company formation.
- Sector
- Business Products and Services (B2B)
- HQ
- Chicago, IL, United States
- Founded
- 2010
- Employees
- 28
- Website
- paragonbiosci.com/
- Ownership
- Privately Held (backing)
Paragon Biosciences doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Paragon Biosciences shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Paragon Biosciences in its N-PORT filings yet. We sweep new filings monthly.